Abstract:Hereditary peripheral neuropathies called Charcot-Marie-Tooth (CMT) disease affect the sensory nerves as well as motor neurons. CMT diseases are composed of a heterogeneous group of diseases. They are characterized by symptoms such as muscle weakness and wasting. Type 2 CMT (CMT2) disease is a neuropathy with blunted or disrupted neuronal morphological differentiation phenotypes including process formation of peripheral neuronal axons. In the early stages of CMT2, demyelination that occurs in Schwann cells (glial cells) is rarely observed. CMT2W is an autosomal-dominant disease and is responsible for the gene encoding histidyl-tRNA synthetase 1 (HARS1), which is a family molecule of cytoplasmic aminoacyl-tRNA synthetases and functions by ligating histidine to its cognate tRNA. Despite increasing knowledge of the relationship of mutations on responsible genes with diseases, it still remains unclear how each mutation affects neuronal differentiation. Here we show that in neuronal N1E-115 cells, a severe Asp364-to-Tyr (D364Y) mutation of HARS1 leads to formation of small aggregates of HARS1 proteins; in contrast, wild type proteins are distributed throughout cell bodies. Expression of D364Y mutant proteins inhibited process formation whereas expression of wild type proteins possessed the normal differentiation ability to grow processes. Pretreatment with the antiepileptic valproic acid recovered inhibition of process formation by D364Y mutant proteins through the c-Jun N-terminal kinase signaling pathway. Taken together, these results indicate that the D364Y mutation of HARS1 causes HARS1 proteins to form small aggregates, inhibiting process growth, and that these effects are recovered by valproic acid. This could be a potential therapeutic drug for CMT2W at the cellular levels.

CMT2D neuropathy is linked to the neomorphic binding activity of glycyl-tRNA synthetase

A New Locus for Autosomal Dominant Charcot-Marie-Tooth Disease Type 2 (CMT2L) Maps to Chromosome 12Q24

Aberrant GlyRS-HDAC6 Interaction Linked to Axonal Transport Deficits in Charcot-Marie-Tooth Neuropathy

Alternative stable conformation capable of protein misinteraction links tRNA synthetase to peripheral neuropathy.

A Novel Mutation of LRSAM1 in a Chinese Family with Charcot-Marie-Tooth Disease

Neuropilin 1 sequestration by neuropathogenic mutant glycyl-tRNA synthetase is permissive to vascular homeostasis

Charcot–Marie–Tooth disease-associated mutant tRNA synthetases linked to altered dimer interface and neurite distribution defect

Charcot-Marie-tooth disease type 2A: An update on pathogenesis and therapeutic perspectives

Clinical,pathological and Genetic Studies in a Chinese Charcot-Marie-Tooth Disease Type 2 Family

Diverse CMT2 neuropathies are linked to aberrant G3BP interactions in stress granules.

SIRT2-knockdown Rescues GARS-induced Charcot-Marie-Tooth Neuropathy

Mice Carrying an Analogous Heterozygous Dynamin 2 K562E Mutation That Causes Neuropathy in Humans Develop Predominant Characteristics of a Primary Myopathy

A Novel TFG C.793c>g Mutation in a Chinese Pedigree with Charcot‐Marie‐Tooth Disease 2

Charcot-Marie-Tooth: From Molecules to Therapy

A Novel RAB7 Mutation in a Chinese Family with Charcot-Marie-Tooth Type 2B Disease.

Transcriptional dysregulation by a nucleus-localized aminoacyl-tRNA synthetase associated with Charcot-Marie-Tooth neuropathy

CMT2N-causing aminoacylation domain mutants enable Nrp1 interaction with AlaRS

Axonal Charcot-Marie-Tooth Disease: from Common Pathogenic Mechanisms to Emerging Treatment Opportunities

Impaired protein translation in Drosophila models for Charcot–Marie–Tooth neuropathy caused by mutant tRNA synthetases

Boosting peripheral BDNF rescues impaired in vivo axonal transport in CMT2D mice

The Antiepileptic Valproic Acid Ameliorates Charcot-Marie-Tooth 2W (CMT2W) Disease-Associated HARS1 Mutation-Induced Inhibition of Neuronal Cell Morphological Differentiation Through c-Jun N-terminal Kinase